Market Capitalization (Millions $) |
37 |
Shares
Outstanding (Millions) |
107 |
Employees |
600 |
Revenues (TTM) (Millions $) |
- |
Net Income (TTM) (Millions $) |
-1 |
Cash Flow (TTM) (Millions $) |
5 |
Capital Exp. (TTM) (Millions $) |
0 |
Lianbio
LianBio is a biopharmaceutical company headquartered in Shanghai, China. The company was established in 2019 by industry veterans with decades of experience in drug development, commercialization, and investment from leading biopharmaceutical companies such as Pfizer, Amgen, and Johnson & Johnson.
LianBio aims to become a market leader in the development and commercialization of innovative therapies for unmet medical needs in China and other global markets. The company's strategy is to leverage its network, knowledge, and expertise to identify promising drug candidates from academia and industry, and then to provide funding, development resources, and global commercialization capabilities to bring these therapies to market.
LianBio has a broad pipeline of more than ten programs in various stages of development, ranging from early-stage research to late-stage clinical trials. The company focuses on a range of therapeutic areas, including oncology, immunology, metabolic diseases, and neurology. LianBio's programs include both small molecules and biologics, with a strong emphasis on precision medicine and personalized therapies.
LianBio has established partnerships with leading academic and research institutions, pharmaceutical companies, and investors across the globe, including in the US, Europe, and Asia. The company has raised significant capital from leading investors, including Hillhouse Capital, Boyu Capital, Sequoia Capital China, and Temasek.
LianBio has a strong management team with extensive experience in drug development and commercialization, including key executives who have held senior leadership positions in some of the world's leading biopharmaceutical companies. The company's management team is supported by more than 200 employees who are dedicated to advancing the company's mission of improving patients' lives through innovative therapies.
Overall, LianBio is a rapidly growing biopharmaceutical company with a broad pipeline of innovative therapies and a strong focus on precision medicine and personalized therapies. With a strong management team, partnerships with leading institutions and investors, and a commitment to advancing the science of drug development, LianBio is poised for long-term success in the rapidly evolving biopharmaceutical industry.
Company Address: 103 Carnegie Center Drive Princeton 8540 NJ
Company Phone Number: 486-2308 Stock Exchange / Ticker: NASDAQ LIAN
LIAN is expected to report next financial results on March 27, 2024. |
|
|